CHEMED CORP (CHE) Form 8-K — Oct 27, 2026
Chemed (NYSE: CHE) reported Q3 2026 revenue of $690.9 million, up 10.6% year-over-year, with GAAP diluted EPS of $5.45 (+22.2%) and adjusted diluted EPS of $6.75 (+28.1%). The VITAS hospice segment drove the beat with net patient revenue of $457.4 million (+12.2%), average daily census up 9.4%, and adjusted EBITDA (ex-Medicare Cap) up 31.4% to $92.5 million; Medicare Cap charges fell to $828,000 from $6.1 million a year ago. Roto-Rooter grew revenue 7.5% to $233.5 million, but adjusted EBITDA declined 2.5% to $48.2 million on a 17.1% jump in SG&A; it also re-acquired California franchise territories for approximately $62.5 million.
Key figures
- Eps
- 5.45
- Revenue
- 690900000
- Guidance
- Expects to be at or slightly above the high-end of full-year 2026 adjusted EPS guidance issued July 28, 2026.
- Net Income
- 71648000
- Total Debt
- 236000000
- Cash Position
- 48400000
- Credit agreement
- $450 million five-year revolving credit facility, SOFR + 100bps
- Vitas admissions
- 18,995 (+7.2%)
- Roto rooter revenue
- $233.5 million (+7.5%)
- Adjusted diluted eps
- 6.75
- Q3 share repurchases
- 125,000 shares for $66.0 million at $528.24 avg
- Vitas avg daily census
- 24,428 (+9.4%)
- Trailing 12mo repurchases
- 1,235,000 shares at $427.62 avg
- Vitas net patient revenue
- $457.4 million (+12.2%)
- Roto rooter adjusted ebitda
- $48.2 million (-2.5%)
- Medicare cap accrual q3 2025
- 6100000
- Medicare cap accrual q3 2026
- 828000
- Franchise territory acquisition
- Approximately $62.5 million for California territories
- Remaining repurchase authorization
- $73.7 million
- Vitas adjusted ebitda ex medicare cap
- $92.5 million (+31.4%)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.